| |
| Target Portfolio >> Excellent Safety Profiles |
|
| PAP-1: |
- 6-month daily oral administration at 50 mg/kg/day in rats.
- 28-day daily oral administration at 25 mg/kg/day in non-human primates.
|
| ShK-186: |
- 28-day daily subcutaneous injections at 500 mg/kg/day.
|
No behavioral, organ, blood cell or blood chemistry toxicity observed. |
| |
|
|
 |
|
| February 2011 |
| February 2011 AIRMID partners with Circassia to develop topical PAP-1 |
|
| January 2010 |
| Joe Sum joins
AIRMID Board of Directors |
| July 2009 |
AIRMID partners with Kineta
to develop ShK peptides
|
|
more... |
|
